Format

Send to

Choose Destination
Endokrynol Pol. 2020;71(1):100-101. doi: 10.5603/EP.a2019.0048. Epub 2019 Nov 4.

Life-threatening hypophosphataemia secondary to zoledronic acid implementation in a middle-age patient who presented with advanced osteolysis in the course of multiple myeloma.

Author information

1
Department of Internal Medicine and Endocrinology, University Clinical Centre, Medical University of Warsaw, Warsaw, Poland. m.a.radziszewski92@gmail.com.
2
Department of Internal Medicine and Endocrinology, University Clinical Centre, Medical University of Warsaw, Warsaw, Poland.
3
2nd Department of Clinical Radiology, University Clinical Centre, Medical University of Warsaw, Warsaw, Poland.

Abstract

Not required for Clinical Vignette.

KEYWORDS:

hypophosphatemia; multiple myeloma; osteolysis; zoledronic acid

PMID:
31681977
DOI:
10.5603/EP.a2019.0048
Free full text

Supplemental Content

Full text links

Icon for Via Medica Medical Publishers
Loading ...
Support Center